US Patent

US10849847 — Compositions and methods for treating rosacea and acne

Method of Use · Assigned to Foamix Pharmaceuticals Ltd · Expires 2037-09-08 · 11y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compositions and methods for treating rosacea and acne using a gel or foam composition with a tetracycline antibiotic.

USPTO Abstract

Provided are compositions and methods for treating rosacea and acne. Specifically, a gel or foam composition having a tetracycline antibiotic and uses thereof for treating rosacea and acne are provided.

Drugs covered by this patent

minocycline-hydrochloride (MINOCYCLINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2647`	—	minocycline-hydrochloride

Patent Metadata

Patent number: US10849847
Jurisdiction: US
Classification: Method of Use
Expires: 2037-09-08
Drug substance claim: No
Drug product claim: No
Assignee: Foamix Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.